Discovery of ASP5286: A novel non-immunosuppressive cyclophilin inhibitor for the treatment of HCV

Makino, Takuya; Yoshimura, Seiji; Neya, Masahiro; Yamanaka, Toshio; Sawada, Masae; Tsujii, Eisaku; Barrett, David

doi:10.1016/j.bmcl.2020.127308

Cited by 2 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, Avasimibe, an inhibitor of Apo B and Apo E secretion, is a clinically approved HTA and can be used against all 6 major genotypes of HCV [39]. Likewise, ASP5286, a potential inhibitor of HCV has been discovered that targets cyclophilin [44].…”

Section: Therapeutic Strategiesmentioning

confidence: 99%

A review on hepatitis C virus: role of viral and host-cellular factors in replication and existing therapeutic strategies

Butt

Shahid

Hassan

et al. 2022

Egypt Liver Journal

View full text Add to dashboard Cite

Background Hepatitis C virus, a member of Flaviviridae is a single-stranded positive-sense RNA virus infecting 62–79 million people around the globe. This blood-borne virus is one of the leading causes of liver diseases worldwide. This review aims to identify novel potential genes linked to cellular host factors, as well as revise the roles of each gene in hepatitis C Virus infection. This review also aims to provide a comprehensive insight into therapeutic advancements against HCV. Methods For this review article, 190 articles were searched via PubMed Central, Bio-One, National Academy of Science, Google Scholar, and Worldwide Science. 0ut of these 190 studies, 55 articles were selected for this review. The inclusion of articles was done on the criteria of high citation and Q1 ranking. Results The information gathered from previously published articles highlighted a critical link between host-cellular factors that are important for HCV infection. Conclusion Although many advancements in HCV treatment have been made like DAAs and HTAs, the development of a completely effective HCV therapy is still a challenge. Further research on combinations of DAAs and HTAs can help in developing a better therapeutic alternative. Keywords: Hepatitis C virus, Replication cycle, Non-structural proteins, Host-cellular factors, Treatment strategies

show abstract

Section: Therapeutic Strategiesmentioning

confidence: 99%

A review on hepatitis C virus: role of viral and host-cellular factors in replication and existing therapeutic strategies

Butt

Shahid

Hassan

et al. 2022

Egypt Liver Journal

View full text Add to dashboard Cite

show abstract

“…CsA can form a cytoplasmic ternary complex with cellular protein cyclophilin A (CypA) and the phosphatase calcineurin ( 2 , Figure ). CypA is known as peptidyl prolyl isomerase A (PPIA), and CypA can catalytically regulate the cis-trans isomerization of proline peptide bonds, which are important for protein folding and function. On the contrary, the interaction between the CypA–CsA complex and calcineurin can prevent calcineurin from its dephosphorylating the transcriptional regulator nuclear factor of activated T-cells (NFATs), thereby preventing the production of proteins associated with the immune response …”

mentioning

confidence: 99%

Semisynthesis of CRV431

Zhang

et al. 2021

Org. Lett.

View full text Add to dashboard Cite

The non-immune-suppressive cyclophilin inhibitor CRV431 is a clinical candidate to cure nonalcoholic steatohepatitis (NASH) and has the potential to treat liver fibrosis and cancer incidence. Herein we report a concise chemical semisynthesis of CRV431 in four steps from the commercially available cyclosporine, featuring in this the flow-chemistry-based methylenation an intermolecular ring-closing metathesis and a Rh-catalyzed diastereoselective hydrogenation.

show abstract

Discovery of ASP5286: A novel non-immunosuppressive cyclophilin inhibitor for the treatment of HCV

Cited by 2 publications

References 35 publications

A review on hepatitis C virus: role of viral and host-cellular factors in replication and existing therapeutic strategies

A review on hepatitis C virus: role of viral and host-cellular factors in replication and existing therapeutic strategies

Semisynthesis of CRV431

Contact Info

Product

Resources

About